多模态超声整合路径与甲状腺癌精准诊疗范式创新
本综述系统评估高频超声、弹性成像、超声造影及超分辨成像在甲状腺癌筛查-诊断-治疗-随访全流程中的转化价值。方法为系统性文献整合，汇总临床与临床前研究数据。主要结论为多模态超声技术可提升微钙化检出率、诊断特异度、微血管成像能力及消融疗效。
要点
- 高频超声联合AI可提高甲状腺微钙化检出率，有助于早期识别恶性结节。
- 弹性成像Emax阈值联合VEGF、PD-L1等分子指标可提升诊断特异度。
- 超声引导消融联合靶向微泡技术对微小癌有较高完全消融率。
核心结论
- 多模态超声技术包括高频超声、弹性成像、超声造影和超分辨成像，在甲状腺癌全程管理中具有稳健的转化价值。
- 多模态超声整合可显著改善检出率、诊断特异度、微血管成像及治疗疗效，从而支持甲状腺癌精准管理。
研究设计与样本
- 研究类型为系统性文献综述，整合已发表的临床研究与临床前试验数据进行评估。
- 纳入数据涉及高频超声联合人工智能、弹性成像联合分子生物标志物、超分辨成像、超声引导消融等技术。
- 提取的定量参数包括微钙化检出率、以Emax截断值为基础的诊断特异度、空间分辨率、微血管密度、微血管流速及完全消融率。
- 同时回顾了超声影像组学与基因组学的新证据。
关键影像表现/征象
- 10-24 MHz高频超声探头联合AI对小于1 mm微钙化的检出率为91.4%。
- 超分辨成像突破了50 µm分辨率限制，可进行三维微血管拓扑重建。
- 超分辨成像可量化微血管密度和微血管流速。
诊断标准与关键数值
- 10-24 MHz高频超声联合AI对小于1 mm微钙化的检出率为91.4%。
- 弹性成像Emax≥30.65 kPa联合VEGF、PD-L1等分子影像生物标志物时，诊断特异度达93.6%。
- 超声引导消融联合靶向微泡技术对微小癌的完全消融率为92.3%。
临床应用与阅片要点
- 日常报告中对可疑甲状腺结节可采用高频超声联合AI评估微钙化，提高恶性征象检出能力。
- 弹性成像可将Emax 30.65 kPa作为参考阈值之一，并结合分子生物标志物辅助诊断。
- 超分辨成像可用于三维微血管拓扑重建及微血管密度、流速量化，拓宽微血管评估维度。
- 对甲状腺微小癌行超声引导消融时，可关注联合靶向微泡技术的应用价值。
局限性
- 原文为综述性质，汇总的临床研究之间存在异质性，未提供统一对照设计。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
RATIONALE AND OBJECTIVES: Thyroid cancer, the fastest-growing endocrine malignancy, is shifting from morphological evaluation to molecular-functional imaging. This review systematically evaluates the translational value of multimodal ultrasound technologies-high-frequency ultrasound (HFUS), elastography, contrast-enhanced ultrasound (CEUS), and super-resolution imaging (SRI)-across the entire "screening-diagnosis-treatment-follow-up" continuum of thyroid cancer management.
MATERIALS AND METHODS: A systematic literature synthesis was performed, aggregating data from clinical studies and preclinical trials that assessed multimodal ultrasound technologies in thyroid cancer. Key quantitative parameters extracted for analysis included: microcalcification detection rate using HFUS with artificial intelligence (AI), diagnostic specificity based on elastography (Emax cutoff) combined with molecular biomarkers (VEGF, PD-L1), spatial resolution and microvascular metrics (microvessel density [MVD], microvascular flow rate [MFR]) achieved by SRI, and complete ablation rate of ultrasound-guided ablation coupled with targeted microbubble technology. Emerging evidence on ultrasound radiomics and genomics was also reviewed.
RESULTS: Morpho-functional dual-modal assessment using 10-24 MHz HFUS probes integrated with AI achieved a 91.4% detection rate for microcalcifications (<1 mm). Quantitative elastography parameters (Emax ≥30.65 kPa) combined with molecular imaging biomarkers (VEGF, PD-L1) elevated diagnostic specificity to 93.6%. SRI broke the 50 µm resolution barrier, enabling three-dimensional microvascular topology reconstruction and quantification of MVD and MFR. Ultrasound-guided ablation together with targeted microbubble technology attained a 92.3% complete ablation rate for microcarcinomas. The review further identified frontier integration of ultrasound radiomics and genomics as multidimensional evidence for precision management.
CONCLUSION: Multimodal ultrasound technologies (HFUS, elastography, CEUS, SRI) provide robust translational value across the thyroid cancer care continuum, significantly improving detection, diagnostic specificity, microvascular imaging, and therapeutic efficacy, thereby supporting precision thyroid cancer management.
引用
- Zhang, Wang, Deng, et al. Multimodal Ultrasound Integration Pathways and Paradigm Innovations in Precision Diagnosis and Treatment of Thyroid Cancer. Acad Radiol. 2026. PMID: 42230172. doi:10.1016/j.acra.2026.05.005
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。